Skip to main content

Novel Rx

      RT @doctorRBC: Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed ve
      2 years 5 months ago
      Congenital malformations after intra-uterine exposure to non-TNFi when compared to certolizumab showed vedolizumab and belimumab were associated with higher CMs. Vedolizumab showed specific CM pattern (corpus collosum agenesis). @RheumNow #EULAR2022 ABST#OP0129 https://t.co/wgRlm9QLgW
      RT @doctorRBC: No significant difference in malignancy risk in patients with rheumatic disease and a prior history of ma
      2 years 5 months ago
      No significant difference in malignancy risk in patients with rheumatic disease and a prior history of malignancy, who started bDMARDs or tsDMARDs. Interestingly IL-17i had 0 malignancy events and CD-20i were next lowest. @RheumNow #EULAR2022 ABST#OP0138 https://t.co/Mq3YvOrSY8
      RT @ericdeinmd: #EULAR2022 OP0138:
      BIOBADASER registry:
      Cancer risk in AI disease after bDMARD & tsDMARD + h/o prior
      2 years 5 months ago
      #EULAR2022 OP0138: BIOBADASER registry: Cancer risk in AI disease after bDMARD & tsDMARD + h/o prior malignancy ⭐️352 pts w prior malignancy in registry, 32 developed a 2nd incident malignancy 27 rate of cancer/1000 patient years. No diff of cancer or mortality b/w Rx @Rheumnow https://t.co/nTuUooBmzV
      RT @ericdeinmd: #EULAR2022 ASAS/EULAR AxSpA Recs
      ⭐️Last: 2016
      ▶️All: education, exercise, 🚭
      ▶️❌csDMARD
      2 years 5 months ago
      #EULAR2022 ASAS/EULAR AxSpA Recs ⭐️Last: 2016 ▶️All: education, exercise, 🚭 ▶️❌csDMARD for axial disease ▶️TNF/IL17 (or JAK) with high disease: ASDAS>/=2.1 ▶️Monoclonal TNF for uveitis/IBD, high PsO: IL-17 ▶️Sustained remission: tapering of bDMARD "can be considered" @RheumNow https://t.co/3yYU0Vb37r
      RT @KDAO2011: OP0129 Eudravigilance eval pregnancies exposed to non-TNF biologics compared certolizumab. Possible signal
      2 years 5 months ago
      OP0129 Eudravigilance eval pregnancies exposed to non-TNF biologics compared certolizumab. Possible signal w/#vendolizumab: 3 cases of corpus callosum agenesis (2 Crohn’s, 1 UC, 2 assc w/ other CNS malformations). Belim did not show consistent pattern #EULAR2022 @rheumnow https://t.co/BNKaxu6G0c
      RT @KDAO2011: New #SLE drug to pay attention to!
      iberdomide target Ikaros and Aiolos, reduce B cell, reduce autoAb and
      2 years 5 months ago
      New #SLE drug to pay attention to! iberdomide target Ikaros and Aiolos, reduce B cell, reduce autoAb and reduce IFN sig while enhancing regulatory T cells- Prof T Dorner #EULAR2022 @rheumnow https://t.co/q39pxK3gFJ
      RT @AurelieRheumo: Spanish safety registry BIOBADASER 3.0:
      *9000+ pts with IMID treated w/ bio or tsDMARDS
      *352 pts w/ p
      2 years 5 months ago
      Spanish safety registry BIOBADASER 3.0: *9000+ pts with IMID treated w/ bio or tsDMARDS *352 pts w/ prior malignancy *32 incident malignancies -> 27 events/1000PY NO diff between ttmts in incidence or mortality but low number pts in non TNFi groups @RheumNow #EULAR2022 OP0138 https://t.co/8IyC6NdGCF
      RT @Janetbirdope: #ClinicalPearl #SLE Rx tomorrow? Combine #Ritux+#Belimumab variable response, CART Rx for severe refra
      2 years 5 months ago
      #ClinicalPearl #SLE Rx tomorrow? Combine #Ritux+#Belimumab variable response, CART Rx for severe refractory #lupus, antiCD38i, drugs i. RCTs=hope for pts. #EULAR2022 T Dorner @RheumNow @eular_org https://t.co/2BReU5bhG0
      RT @Janetbirdope: ANCA vasculitis guidelines make sense. Less use of cyclophosphamide was already the case, rituximab ca
      2 years 5 months ago
      ANCA vasculitis guidelines make sense. Less use of cyclophosphamide was already the case, rituximab can be for induction & maintenance, I am reluctant though in severe disease to stop maintenance Rx at 1 or 2 yrs and go longer as at least 1/3 will relapse beyond 2 yrs. @RheumNow https://t.co/3xRHWya2Uq